Corrigendum to “Cilengitide inhibits osteoclast adhesion through blocking the αvβ3-mediated FAK/Src signaling pathway” [Heliyon 9(7) (July 2023) e17841]

作者：Dan‐Yang Guo, Zhong-Hua Chen, Yi-Fei Fu, Yueyue Li, Meng-Nan Chen, Jun‐Jie Wu, Zheng‐Dong Yuan, Junxing Ye, Xia Li, Feng‐Lai Yuan · 发表于：Heliyon · 年份：2023 · DOI：10.1016/j.heliyon.2023.e22629 · 被引用次数：4 · 研究领域：Bone Metabolism and Diseases、Bone health and treatments

In the original published version of this article, the authors unintentionally misplaced images in Figure 3A and wish to amend this by providing the correct image of Cilengitid (0.2μm) and the legend. The authors apologize for the errors. Both the HTML and PDF versions of the article have been updated to correct the errors. Cilengitide inhibits osteoclast adhesion through blocking the αvβ3-mediated FAK/Src signaling pathwayGuo et al.HeliyonJune 29, 2023In BriefThe remodeling of actin cytoskeleton of osteoclasts on the bone matrix is essential for osteoclastic resorption activity. A specific regulator of the osteoclast cytoskeleton, integrin αvβ3, is known to provide a key role in the degradation of mineralized bone matrixes. Cilengitide is a potent inhibitor of integrins and is capable of affecting αvβ3 receptors, and has anti-tumor and anti-angiogenic and apoptosis-inducing effects. However, its function on osteoclasts is not fully understood. Here, the cilengitide role on nuclear factor κB ligand-receptor activator (RANKL)-induced osteoclasts was explored. Full-Text PDF Open Access